Schizophrenia/Psychosis

Women with schizophrenia face increased breast cancer risks linked to long-term prolactin-raising antipsychotic use, highlighting the need for regular screenings and tailored treatment strategies.

Discover groundbreaking schizophrenia treatment with xanomeline-trospium, targeting cholinergic pathways for improved symptoms and fewer side effects.

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

In this CME article, learn more about the complexities of neuropsychiatric symptoms in Parkinson disease, including psychosis and cognitive impairment, and effective treatment strategies.

Innovative digital therapeutics like CT-155 are transforming mental health treatment, targeting negative symptoms of schizophrenia and enhancing depression care. Check out this conversation with Shaheen Lakhan, MD, PhD.

It is critical to recognize the early signs of schizophrenia and provide timely intervention to prevent full-blown psychosis in adolescents.

The FDA's removal of clozapine REMS enhances access to treatment, while new educational initiatives empower clinicians to improve patient care.

Learn more about how to best assess and treat tardive dyskinesia.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.

Learn more about the critical link between early adversity and psychosis, and the need for targeted interventions and preventive measures.

Explore the complex role of dopamine in schizophrenia, its impact on symptoms, and potential therapeutic advancements.

Early intervention in schizophrenia enhances recovery, reduces symptoms, and improves quality of life through coordinated specialty care programs across the US.

In this Special Report, explore groundbreaking insights on schizophrenia treatment, early intervention strategies, and the impact of childhood trauma on psychosis.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

Learn more about the latest advancements in schizophrenia treatment and the ongoing battle against stigma during Mental Health Awareness Month.

Check out the pipeline updates from April!

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

How can psychiatric professionals and pharmacists best work together to improve patient care? One pharmacist shares his thoughts.

Different medications for different domains: new treatments are changing the way schizophrenia is managed.

Take a look at the differentiation between prodrome and attenuated psychosis, along with cognitive impairment associated with schizophrenia.

Here's what patients should know about Cobenfy for the treatment of schizophrenia.

Without the scaffolding of the REMS requirement for clozapine, how can you best utilize this treatment?

How can you best transition patients to Cobenfy if they are already taking an antipsychotic medication?

Peripartum psychosis is considered a psychiatric emergency. Here is how an interdisciplinary team can provide the best care.